Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma - art. no. e798

Matthews, GM and Lefebure, M and Doyle, MA and Shortt, J and Ellul, J and Chesi, M and Banks, KM and Vidacs, E and Faulkner, D and Atadja, P and Bergsagel, PL and Johnstone, RW (2013) Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma - art. no. e798. CELL DEATH & DISEASE.

Item Type: Article
Additional Information: pubid: 178 nvp_institute: NIBR contributor_address: Peter MacCallum Canc Ctr, Gene Regulat Lab, East Melbourne, Vic 3002, Australia, Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia geoff.matthews@petermac.org; Peter MacCallum Canc Ctr, Bioinformat Core Facil, East Melbourne, Vic 3002, Australia ; Mayo Clin Arizona, Ctr Comprehens Canc, Scottsdale, AZ USA, Mayo Clin Arizona, Scottsdale, AZ USA ; Peter MacCallum Canc Ctr, Dept Pathol, East Melbourne, Vic 3002, Australia ; Novartis Inst Biomed Res, Cambridge, MA USA ; Peter MacCallum Canc Ctr, Gene Regulat Lab, East Melbourne, Vic 3002, Australia; Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia; Matthews, G M; Peter MacCallum Canc Ctr, Gene Regulat Lab, St Andrews Pl, East Melbourne, Vic 3002, Australia
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22000

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.